https://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0869982001&sourceType=1https://www.ccnmatthews.com/logos/20051018-prometic.gif LAVAL, QUEBEC -- (Marketwired) -- 04/30/13 -- ProMetic Life Sciences Inc. (TSX:PLI) (OTCQX:PFSCF) ("ProMetic" or the "Corporation") announced today the expansion of its existing strategic collaboration with Sartorius Stedim Biotech ("SSB") to include a contribution of equipment to ProMetic's plasma purification facility as well as an agreement for the co-commercialization of PPPS(TM) on a global basis.
Pursuant to the agreement, SSB will provide filtration equipment and other consumables to be integrated in ProMetic's plasma purification plant, which is set to be operational in the fourth quarter of 2013. SSB's strategic contribution represents a significant investment over the next 3 years as plasma derived products manufactured in the GMP facility undergo regulatory approval. The agreement also confirms SSB as a preferred supplier of filtration equipment and consumables for ProMetic's PPPS(TM) licensees. SSB filtration equipment and consumables will be offered as an integral part of ProMetic's offering of plasma purification turnkey processes.